An effective and safe targeted therapy for treatment of Myasthenia gravis

Project description

Innovative tolerance technology for the treatment of autoimmune disease

Myasthenia gravis (MG) is one of the most common chronic autoimmune neuromuscular diseases that causes weakness in the skeletal muscles responsible for breathing and moving parts of the body. Currently, there is no cure for MG, which belongs to the so-called orphan (rare) diseases with an unmet medical need. Toleranzia is a Swedish pharmaceutical company that develops therapies directed at the intrinsic resources of the immune system to treat autoimmune diseases. Under the EU-funded TOL2 project it will address the need for a safe and effective treatment to cure MG. The tolerance technology behind the TOL2 project has the potential to be applied to therapies for other autoimmune diseases.

Fields of science

• social sciences › economics and business › business and management › business models
• medical and health sciences › basic medicine › immunology › autoimmune diseases
• medical and health sciences › basic medicine › neurology
• social sciences › sociology › social issues › unemployment

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

TOLERANZIA AB

Net EU contribution

€ 50 000,00

Address

Erik Dahlbergsgatan 11 A
411 26 Goteborg
Sweden

Region

Södra Sverige › Västsverige › Västra Götalands län

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 21 429,00